Targeted Therapy in China: The Short Answer

Yes, you can get targeted therapy in China. The targeted therapy cost China runs roughly $2,500 to $8,000 per month depending on the drug, hospital tier, and whether you use the public or international channel. That’s 40-70% below typical U.S. list prices for the same or biosimilar equivalents. But access is not automatic. You cannot simply book a targeted therapy regimen from abroad and show up. A Chinese oncologist must review your pathology report, confirm the specific mutation, and write the prescription through a hospital’s pharmacy system. The drugs exist. The expertise exists. The pathway requires coordination.

Who This Is Right For — and Who It Isn’t

Targeted therapy only works when your tumor has a specific genetic driver mutation. EGFR, ALK, ROS1, HER2, BRAF, KRAS G12C — these are the names that matter. If your biopsy or liquid biopsy has already identified one of these mutations, China is a serious option. If you have not had genomic testing yet, that comes first. China’s major cancer centers run comprehensive next-generation sequencing panels, often within 5-7 working days.

Good candidates typically fall into these groups:

• Patients with confirmed EGFR, ALK, ROS1, or other actionable mutations, especially in non-small cell lung cancer
• Patients already on a targeted drug at home who want to continue treatment at lower cost
• Patients whose current drug is not yet approved or is priced out of reach in their home country
• Patients seeking Chinese-approved next-generation inhibitors (e.g., third-generation EGFR TKIs) not yet available elsewhere

Who should not pursue this path? Patients without a confirmed mutation — targeted therapy would be ineffective and potentially harmful. Patients whose disease has progressed on multiple lines of therapy and who need a clinical trial rather than a standard targeted agent. And patients too unstable to travel. A 12-hour flight with uncontrolled pleural effusion or active brain metastases is not wise. Stay home. Stabilize first.

The Options, Compared

When patients ask about getting targeted therapy in China, they are usually choosing between three real pathways. Here is how they stack up.

The public standard pharmacy is cheapest but hardest to navigate without Chinese language skills. The international department adds a coordination layer and English support, typically at 1.5 to 2 times the standard price. Private international hospitals offer the smoothest experience but the highest drug markup. Your choice depends on budget, language comfort, and how much coordination help you have. Many patients start with a written second opinion from a top public hospital oncologist, then decide which channel suits them.

Is Targeted Therapy Available in China? The Drug Landscape in 2025

China’s National Medical Products Administration has approved over 80 targeted oncology drugs. The national reimbursement list (NRDL) now covers many first-, second-, and third-generation targeted agents. That matters because NRDL inclusion drives prices down dramatically — sometimes by 60-80% compared to pre-listing prices. Osimertinib, alectinib, crizotinib, lorlatinib, and multiple EGFR TKIs are all available. Several Chinese-developed drugs, such as icotinib and furmonertinib, are not even sold in Western markets. That cuts both ways. A drug available in China may not be familiar to your home oncologist. Bring documentation. Ask for the generic and brand names. Confirm the molecular target.

For lung cancer specifically, the targeted therapy for lung cancer China price is among the most competitive globally. Third-generation EGFR inhibitors run approximately $1,800 to $3,500 per month through the public channel. ALK inhibitors are pricier — $3,000 to $6,000 monthly. These figures vary by hospital procurement contracts and whether the drug is domestically produced or imported. Domestic biosimilars and me-too inhibitors are consistently cheaper than imported originals. Your Chinese oncologist will typically offer both options and explain the clinical equivalence data.

Best Cancer Hospital Shanghai for Targeted Therapy — and Other Centers That Matter

Shanghai hosts several of China’s strongest oncology programs. Fudan University Shanghai Cancer Center ranks among China’s top 10 for oncology in the Fudan specialty reputation rankings. Its thoracic oncology department handles one of the highest volumes of EGFR-mutated lung cancer cases in the country. Shanghai Chest Hospital is another high-volume center, particularly for lung cancer. Both run in-house molecular diagnostics and have dedicated international patient offices.

But Shanghai is not the only answer. Beijing’s Cancer Hospital of the Chinese Academy of Medical Sciences and Peking University Cancer Hospital are equally strong for targeted therapy prescribing. Guangzhou’s Sun Yat-sen University Cancer Center leads in southern China. Chengdu’s West China Hospital and Hangzhou’s affiliated hospitals round out the picture. You can compare oncology programs across our specialty hospital rankings and browse top-tier hospitals by city. The best hospital for you depends on your specific mutation, prior treatment lines, and where you can practically travel.

How Much Does Targeted Therapy Cost in Beijing? A Realistic Breakdown

Beijing prices run slightly higher than Shanghai for the same drugs, mostly due to higher international department fees. Expect $3,000 to $6,000 monthly for a first-line EGFR TKI through a Beijing public hospital international department. Add $500 to $800 for the initial consultation, imaging, and molecular pathology review. A top-specialist video consultation before travel costs $500 to $800 through our coordination, and that amount is credited in full toward on-the-ground services if you proceed within 90 days.

What is not included: international travel, accommodation, visa fees, and any hospitalization if your oncologist recommends inpatient observation when starting a new drug. Most targeted therapy starts on an outpatient basis. You pick up the prescription monthly. Some hospitals dispense 30 days at a time. Others allow 90-day refills for stable patients. Ask before you commit.

How to Book Targeted Therapy Treatment in China: The Actual Sequence

You cannot book targeted therapy treatment in China the way you book a hotel. The sequence matters. First, send your existing records — pathology report, genomic testing results, imaging, current medication list. A Chinese oncologist reviews them and issues a written second opinion, typically $300 to $500. That opinion tells you whether the Chinese team agrees with your current regimen, suggests alternatives, and confirms drug availability. Second, if you proceed, the hospital schedules an in-person consultation. You travel on an S2 visa, which is the appropriate short-stay category for medical treatment and private affairs. Bring a hospital invitation letter and medical records to support the visa application. Third, the oncologist sees you, reviews your physical status, and writes the prescription. Fourth, the hospital pharmacy dispenses the drug. You pay. You leave with the medication and a treatment plan.

Language is the biggest friction point. Public hospital pharmacies, registration desks, and nursing stations operate in Chinese. A bilingual medical companion who handles queueing, payment, and translation removes most of that friction. Our team provides that service from $300 per day. We do not prescribe, diagnose, or guarantee a specific drug or specialist. We coordinate. The medical decisions belong to the Chinese oncologist and you.

Practical Considerations: Records, Visas, Payment, and Follow-Up

Records first. Chinese oncologists will not prescribe targeted therapy without a pathology report and, ideally, a genomic sequencing report. If your sequencing was done more than six months ago or after a recent progression, expect a request for repeat testing. Bring digital and paper copies. Translate key documents into Chinese if possible — many international departments handle translation, but it slows things down.

Visa category matters. The S2 visa is for short stays for medical treatment and private affairs. It is not a work visa. It is not the M visa, which is for commercial and trade activities only. Applying for the wrong category causes delays. Supporting documents from the hospital strengthen the application. Approval is never guaranteed. Check the latest requirements with the Chinese embassy or consulate in your country before booking flights.

Payment is self-pay in almost all public and international department settings. Bring a credit card with a high limit or arrange wire transfer. Private international hospitals sometimes bill insurers directly. Public hospitals almost never do. You pay, then file for reimbursement with your insurer at home. Confirm coverage before you travel. Some insurers exclude treatment outside your home country. Others require pre-authorization. Get it in writing.

Follow-up after you return home is the part most patients underestimate. Your Chinese oncologist will want updated imaging and lab results at intervals — usually every 2 to 3 months. You need a local oncologist willing to order those tests and share results. Some home oncologists are cooperative. Others are territorial. Sort this out before you leave. A written treatment summary from the Chinese hospital, in English, helps enormously.

Frequently Asked Questions